Volkar Mueller, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, talks on important updates from the European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021, including updated data on trastuzumab deruxtecan and the incidence of interstitial lung disease associated with this approach. Dr Mueller also highlights the novel Trop-2 targeting antibody-drug conjugate which represents a promising therapeutic approach for these patients. This interview took place at the virtual ESMO Breast Cancer Congress 2021.